Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 September 2007, Vol. 110, No. 6, pp. 1942-1949.
Prepublished online as a Blood First Edition Paper on May 14, 2007; DOI 10.1182/blood-2007-03-079699.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Methods and Figures
Right arrow All Versions of this Article:
blood-2007-03-079699v1
110/6/1942    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ong, C. J
Right arrow Articles by Mui, A. L-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ong, C. J
Right arrow Articles by Mui, A. L-F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 13, 2007
Accepted April 22, 2007

Small molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells

Christopher J Ong, Andrew Ming-Lum, Matt Nodwell, Ali Ghanipour, Lu Yang, David E Williams, Joseph Kim, Loutfig Demirjian, Pooran Qasimi, Jens Ruschmann, Li-Ping Cao, Kewei Ma, Stephen W Chung, Vincent Duronio, Raymond J Andersen, Gerald Krystal, and Alice L-F. Mui*

Prostate Centre at Vancouver General Hospital, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada
Dept of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
Dept of Chemistry & Earth & Ocean Sciences, University of British Columbia, Vancouver, British Columbia, Canada
Dept of Biochemistry & Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
Fachbereich Biologie, Chemie, Pharmazie, Takustr, FU-Berlin, Berlin, Germany
Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
Dept of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Dept of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Immunity & Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

* Corresponding author; email: amui{at}interchange.ubc.ca.

Because phosphoinositide 3-kinase (PI3K) plays a central role in cellular activation, proliferation and survival, pharmacological inhibitors targeting components of the PI3K pathway are actively being developed as therapeutics for the treatment of inflammatory disorders and cancer. These targeted drugs inhibit the activity of either PI3K itself or downstream protein kinases. However, a previously unexplored, alternate strategy is to activate the negative regulatory phosphatases in this pathway. The SH2-containing inositol-5'-phosphatase SHIP1 is a normal physiological counter-regulator of PI3K in immune/hematopoietic cells which hydrolyzes the PI3K product phosphatidylinositiol-3,4,5-trisphosphate (PIP3). We now describe the identification and characterization of potent and specific small molecule activators of SHIP1. These compounds represent the first small molecule activators of a phosphatases, and are able to activate recombinant SHIP1 enzyme in vitro and stimulate SHIP1 activity in intact cells macrophage and mast cells. Mechanism of activation studies with these compounds suggests that they bind a previously undescribed, allosteric activation domain within SHIP1. Furthermore, in vivo administration of these compounds was protective in mouse models of endotoxemia and acute cutaneous anaphylaxis suggesting that SHIP1 agonists could be used therapeutically to inhibit the PI3K pathway.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
S. J. Harris, R. V. Parry, J. Westwick, and S. G. Ward
Phosphoinositide Lipid Phosphatases: Natural Regulators of Phosphoinositide 3-Kinase Signaling in T Lymphocytes
J. Biol. Chem., February 1, 2008; 283(5): 2465 - 2469.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020